Development by Third Parties Sample Clauses

Development by Third Parties. Except as otherwise set forth herein, Publisher shall not provide Sony Materials or SCEA's Confidential Information to any third party. Publisher shall be responsible for determining that third parties meet the criteria set forth herein. Publisher may contract with a third party for development of Licensed Products, provided that such third party is: (i) a Licensed Publisher, (ii) a Licensed Developer, or (iii) an SCEA-authorized subcontractor in compliance with the provisions of Section 16.6. Publisher shall notify SCEA in writing of the identity of any such third party within thirty (30) days of entering into an agreement or other arrangement with the third party.
Sample 1Sample 2Sample 3See All (19)
AutoNDA by SimpleDocs
Development by Third Parties. Except as otherwise set forth herein, Publisher shall not provide SCE Materials or SCEA’s Confidential Information to any third party. Publisher shall be responsible for determining that third parties meet the criteria set forth herein. Publisher may contract with a third party for development of Licensed PSP Products, provided that such third party is: (i) a Licensed PSP Publisher, (ii) a Licensed PSP Developer, or (iii) an SCEA-authorized subcontractor in compliance with the provisions of Section 16.6. Publisher shall notify SCEA in writing of the identity of any such third party within thirty (30) days of entering into an agreement or other arrangement with the third party.
Sample 1Sample 2Sample 3See All (6)
Development by Third Parties. In the event that the NDP elects not to continue the development and commercialization of the abandoned Independent Product as its own Independent Product or does not use commercially reasonably efforts to develop or commercialize the abandoned Independent Product, the Parties may, by mutual written agreement, license Third Parties to pursue such Product opportunities, or dispose of any such Product opportunity in any other manner that is mutually agreeable. If the Parties are unable to come to a mutual written agreement, then the IDP for the Product shall have final approval authority. In any such out-licensing arrangement, any outstanding payment and/or royalty obligations incurred from grants, external formulation efforts, or other contractual sources will be incorporated into the out-license agreement. The IDP shall be solely responsible for all Costs and expenses associated with out-licensing the Independent Products and shall retain all payments or royalties from such third party except the NDP shall retain its rights to a royalty pursuant to Section 5.6 and Section 9.7.
Sample 1Sample 2Sample 3
Development by Third Parties. In certain circumstances, the Parties may agree that a particular Product may be more advantageously pursued by one or more Third Parties. In such cases, the Parties may, by mutual written agreement, license Third Parties to pursue such Product opportunities, or dispose of any such Product opportunity in any other manner that is mutually agreeable. For a Joint Development Compound, if the LDP wishes to involve a Third Party in development and commercialization efforts, the LDP shall first offer the opportunity to the other Party. The other Party shall have no longer than thirty (30) days to provide a written response of their interest in the opportunity to the LDP. If the other Party decides not to accept the opportunity and the Parties are unable to come to a mutual written agreement with respect to involvement by the Third Party, then the Lead Development Party for the Product shall have final approval authority. For a Joint Development Compound/IV, the Parties shall come to a mutual written agreement. In any such out-licensing arrangement, any outstanding payment and/or royalty obligations incurred from grants, external formulation efforts, or other contractual sources will be incorporated into the out-license agreement. Chiron and PathoGenesis will share equally on a 50%-50% basis or as otherwise agreed in writing by the Parties the costs of arranging for any such dispositions and the consideration received in exchange therefor, including upfronts, milestones and royalties, after true-up of expense consideration to date.
Sample 1Sample 2
Development by Third Parties. Except as otherwise set forth herein, Publisher shall not provide SCEK Materials or SCEK’s Confidential Information to any third party. Publisher shall be responsible for determining that third parties meet the criteria set forth herein. Publisher may contract with a third party for development of Licensed Products, provided that such third party is: (i) a Licensed Publisher, (ii) a Licensed Developer, or (iii) an SCEK-authorized subcontractor in compliance with the provisions of Section 16.6. Publisher shall notify SCEK in writing of the identity of any such third party within thirty (30) days of entering into an agreement or other arrangement with the third party.
Sample 1
Development by Third Parties. Except as otherwise set forth herein, Developer shall not provide Sony Materials or SCEA's Confidential Information to any third party. Developer shall be responsible for determining that third parties meet the criteria set forth herein. Developer may contract with a third party for development of Licensed Products, provided that such third party is: (i) a Licensed Developer, (ii) a Licensed Publisher, or (iii) an SCEA-authorized subcontractor in compliance with the provisions of Section 13.6. Developer shall notify SCEA in writing of the identity of any such third party within thirty (30) days of entering into an agreement or other arrangement with the third party.
Sample 1

Related to Development by Third Parties

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards the next clinical Development milestone or approval milestone, as described in Sections 7.4.2 or 7.4.3, respectively. If Novartis (itself or through its Affiliates or sublicensees) fails to dedicate commercially reasonable efforts, during any [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards such next milestone, then any dispute regarding Novartis’ failure of development diligence with respect to such Profile shall be resolved in accordance with Article 13.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Development Work Do, or cause to be done, such development and other work as may be reasonably necessary to protect from diminution and production capacity of the Mortgaged Property and each producing well thereon.

  • Development Efforts Genentech will use commercially reasonable and diligent efforts to develop C2B8, including pursuing preclinical development and clinical development of C2B8 and obtaining Regulatory Approvals therefor in all countries in the Licensed Territory, taking into account the scientific and commercial potential of C2B8, including, without limitation, each of the potential indications in the Field for C2B8. Within ninety (90) days of the Original Effective Date, Genentech agrees to provide IDEC with a written development strategy for C2B8 in the Licensed Territory indicating (i) whether Genentech will develop C2B8 alone or with a partner in Europe, (ii) the identity of its European partner (if any), and (iii) a list of clinical trials which Genentech would conduct for C2B8 approval in Europe assuming adequate quantities of C2B8 are available.

Time is Money Join Law Insider Premium to draft better contracts faster.